肺癌診斷市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、檢測方法、地區和競爭格局分類，2020-2030年預測

2024年全球肺癌診斷市場規模為15.4億美元，預計2030年將以6.99%的複合年成長率成長至23.1億美元。全球肺癌診斷市場涵蓋了用於肺癌早期檢測和精準分型的各種技術和流程。市場成長的主要促進因素是全球肺癌發生率的不斷攀升以及人們對早期篩檢益處的認知不斷提高。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球肺癌診斷市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（小細胞肺癌、非小細胞肺癌）
  • 依檢測方法（影像檢查、切片、痰細胞學檢查、分子檢測、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美肺癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲肺癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區肺癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲肺癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲肺癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球肺癌診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Sanofi SA
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen NV
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Lung Cancer Diagnostics Market, valued at USD 1.54 Billion in 2024, is projected to experience a CAGR of 6.99% to reach USD 2.31 Billion by 2030. The Global Lung Cancer Diagnostics Market encompasses a diverse range of technologies and procedures utilized for the early detection and precise characterization of lung cancer. Market growth is primarily driven by the escalating global incidence of lung cancer and heightened awareness surrounding the benefits of early screening.

Key Market Drivers

The increasing global incidence of lung cancer represents a fundamental driver for the diagnostics market. This rising number of new cases directly necessitates expanded diagnostic capabilities for early detection and precise staging, which are vital for effective treatment planning and improved patient outcomes. The escalating incidence creates continuous demand on healthcare systems for accessible diagnostic tools, encompassing advanced imaging modalities and comprehensive molecular profiling. According to the American Cancer Society and the International Agency for Research on Cancer, in April 2024, "Global Cancer Statistics, 2024" reported an estimated 2.5 million cases of lung cancer were newly diagnosed worldwide in 2022.

Key Market Challenges

The substantial capital investment required for advanced diagnostic technologies poses a notable challenge to the expansion of the Global Lung Cancer Diagnostics Market. The high acquisition, installation, and ongoing maintenance costs associated with state-of-the-art imaging equipment, advanced molecular profiling platforms, and specialized laboratory infrastructure significantly limit their widespread accessibility and adoption. This financial barrier is particularly impactful in emerging economies, where healthcare budgets are often constrained and robust medical infrastructure is less developed.

Key Market Trends

The expansion of global lung cancer screening programs represents a significant trend driving the diagnostics market by systematically increasing the early detection of the disease. These initiatives, increasingly backed by updated guidelines, broaden the eligible population for low-dose computed tomography (LDCT) screening, leading to a greater demand for imaging equipment, skilled radiologists, and subsequent diagnostic procedures. For instance, according to the American Cancer Society, in June 2024, a study found that the up-to-date lung cancer screening prevalence in the United States was 18.1% in 2022, highlighting ongoing efforts to improve screening rates. This programmatic expansion ensures that more individuals at high risk are undergoing regular examinations, facilitating earlier diagnosis and intervention.

Key Market Players

• Sanofi S.A.
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen N.V.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

Report Scope:

In this report, the Global Lung Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Diagnostics Market, By Type:

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer

Lung Cancer Diagnostics Market, By Test:

• Imaging Test
• Biopsy
• Sputum Cytology
• Molecular Test
• Others

Lung Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Diagnostics Market.

Available Customizations:

Global Lung Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer)
  • 5.2.2. By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Test
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Test
  • 6.3.2. Canada Lung Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Test
  • 6.3.3. Mexico Lung Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Test

7. Europe Lung Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Test
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Test
  • 7.3.2. France Lung Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Test
  • 7.3.3. United Kingdom Lung Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Test
  • 7.3.4. Italy Lung Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Test
  • 7.3.5. Spain Lung Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Test

8. Asia Pacific Lung Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Test
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Test
  • 8.3.2. India Lung Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Test
  • 8.3.3. Japan Lung Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Test
  • 8.3.4. South Korea Lung Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Test
  • 8.3.5. Australia Lung Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Test

9. Middle East & Africa Lung Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Test
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Test
  • 9.3.2. UAE Lung Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Test
  • 9.3.3. South Africa Lung Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Test

10. South America Lung Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Test
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Test
  • 10.3.2. Colombia Lung Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Test
  • 10.3.3. Argentina Lung Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Test

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Roche Diagnostics Corporation
• 15.3. BioMerieux SA
• 15.4. Qiagen N.V.
• 15.5. Agilent Technologies, Inc.
• 15.6. Thermo Fisher Scientific Inc.
• 15.7. AstraZeneca plc
• 15.8. Illumina Inc.
• 15.9. Johnson & Johnson
• 15.10. Abbott Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer